Fluoxetine potentiation of omega-3 fatty acid antidepressant effect: Evaluating pharmacokinetic and brain fatty acid-related aspects in rodents

CARLOS HORACIO LAINO, PILAR GARCIA, MARÍA FERNANDA PODESTÁ, CHRISTIAN HÖCHT, NORA SLOBODIANIK, ANALÍA REINÉS

JOHN WILEY & SONS INC

Lugar: New York; Año: 2014 vol. 103 p. 3316 - 3316

e previously reported that combined fluoxetine administration at antidepressant doses renders additive antidepressant effects, whereas non-antidepressant doses potentiate the omega-3 fatty acid antidepressant effect. In the present study, we aimed to evaluate putative pharmacokinetic and brain omega-3 fatty acid-related aspects for fluoxetine potentiation of omega-3 fatty acid antidepressant effect in rats. Coadministration of omega-3 fatty acids with a non-antidepressant dose of fluoxetine (1 mg/kg day) failed to affect both brain fluoxetine concentration and norfluoxetine plasma concentration profile. Fluoxetine plasma concentrations remained below the sensitivity limit of the detection method. Either antidepressant (10 mg/kg day) or non-antidepressant (1 mg/kg day) doses of fluoxetine in combination with omega-3 fatty acids increased hippocampal docosapentaenoic acid (DPA, 22:5 omega-3) levels. Although individual treatments had no effects on DPA concentration, DPA increase was hig